|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
70,650,000 |
Market
Cap: |
3.28(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.62 - $89.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
22,948 |
163,087 |
338,087 |
Total Sell Value |
$0 |
$1,362,031 |
$11,023,312 |
$20,394,162 |
Total People Sold |
0 |
2 |
4 |
4 |
Total Sell Transactions |
0 |
2 |
13 |
20 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bolzon Bradley J Phd |
Director |
|
2020-06-22 |
4 |
AS |
$72.51 |
$725,069 |
I/I |
(10,000) |
584,190 |
|
- |
|
Ho Tony W |
Executive VP, Head of R&D |
|
2020-06-22 |
4 |
AS |
$70.14 |
$16,062 |
D/D |
(229) |
40,676 |
|
- |
|
Treco Douglas A |
Director |
|
2020-06-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,000 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2020-06-02 |
4 |
D |
$66.26 |
$51,617 |
D/D |
(779) |
170,747 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2020-06-01 |
4 |
AS |
$63.57 |
$1,117,266 |
D/D |
(17,275) |
171,526 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2020-06-01 |
4 |
OE |
$1.81 |
$31,268 |
D/D |
17,275 |
188,801 |
|
- |
|
Novak Rodger |
President |
|
2020-05-26 |
4 |
AS |
$70.27 |
$2,573,006 |
D/D |
(36,616) |
748,007 |
|
- |
|
Ho Tony W |
Executive VP, Head of R&D |
|
2020-05-26 |
4 |
AS |
$70.14 |
$427,854 |
D/D |
(6,100) |
40,905 |
|
- |
|
Novak Rodger |
President |
|
2020-05-22 |
4 |
AS |
$70.01 |
$937,014 |
D/D |
(13,384) |
784,623 |
|
- |
|
Ho Tony W |
Executive VP, Head of R&D |
|
2020-05-22 |
4 |
AS |
$70.05 |
$42,030 |
D/D |
(600) |
47,005 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2020-05-20 |
4 |
AS |
$65.28 |
$698,039 |
D/D |
(10,693) |
171,526 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2020-05-20 |
4 |
OE |
$1.81 |
$19,354 |
D/D |
10,693 |
182,219 |
|
- |
|
Novak Rodger |
President |
|
2020-05-19 |
4 |
AS |
$65.00 |
$3,250,000 |
D/D |
(50,000) |
798,007 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2020-05-19 |
4 |
AS |
$65.16 |
$280,644 |
D/D |
(4,307) |
171,526 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2020-05-19 |
4 |
OE |
$1.81 |
$7,796 |
D/D |
4,307 |
175,833 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2020-05-11 |
4 |
AS |
$60.38 |
$1,509,971 |
D/D |
(25,000) |
20,000 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2020-05-11 |
4 |
OE |
$5.86 |
$146,500 |
D/D |
25,000 |
45,000 |
|
- |
|
Ho Tony W |
Executive VP, Head of R&D |
|
2020-03-06 |
4 |
D |
$52.64 |
$82,276 |
D/D |
(1,563) |
47,605 |
|
- |
|
Ho Tony W |
Executive VP, Head of R&D |
|
2020-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,333 |
49,168 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2020-03-02 |
4 |
D |
$52.74 |
$41,876 |
D/D |
(794) |
171,526 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2019-12-16 |
4 |
OE |
$1.81 |
$14,480 |
D/D |
8,000 |
172,320 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2019-12-01 |
4 |
D |
$71.65 |
$53,093 |
D/D |
(741) |
164,320 |
|
- |
|
Cagnoni Pablo J |
Director |
|
2019-11-12 |
4 |
AS |
$55.00 |
$412,500 |
D/D |
(7,500) |
0 |
|
- |
|
Cagnoni Pablo J |
Director |
|
2019-11-12 |
4 |
OE |
$5.59 |
$41,925 |
D/D |
7,500 |
7,500 |
|
- |
|
Cagnoni Pablo J |
Director |
|
2019-10-30 |
4 |
AS |
$52.00 |
$390,000 |
D/D |
(7,500) |
0 |
|
- |
|
483 Records found
|
|
Page 9 of 20 |
|
|